EGFR and non-small cell lung carcinoma: Preliminary clinical evidence also supports the potential for this combination, as demonstrated in an ongoing Phase I/II study where concurrent osimertinib plus gefitinib for the first-line treatment of EGFR-mutated NSCLC resulted in an ORR of 85% with rapid plasma clearance of the EGFR mutation32.